002082 万邦德
午间休市 02-25 11:30:00
资讯
新帖
简况
2月10日万邦德（002082）涨停分析：国家专项、FDA认定、战略合作驱动
证券之星 · 02-10
2月10日万邦德（002082）涨停分析：国家专项、FDA认定、战略合作驱动
异动快报：万邦德（002082）2月10日10点10分触及涨停板
证券之星 · 02-10
异动快报：万邦德（002082）2月10日10点10分触及涨停板
万邦德（002082）披露独立董事任期即将届满公告，2月6日股价上涨7.39%
证券之星 · 02-06
万邦德（002082）披露独立董事任期即将届满公告，2月6日股价上涨7.39%
万邦德：公司医疗设备代理以南非为基地服务南部非洲地区
证券之星 · 02-06
万邦德：公司医疗设备代理以南非为基地服务南部非洲地区
万邦德（002082）披露石杉碱甲控释片Ⅱ、Ⅲ期临床试验完成100例受试者入组公告，2月2日股价下跌0.19%
证券之星 · 02-02
万邦德（002082）披露石杉碱甲控释片Ⅱ、Ⅲ期临床试验完成100例受试者入组公告，2月2日股价下跌0.19%
股市必读：万邦德（002082）预计2025年全年归属净利润亏损9000万元至1.7亿元
证券之星 · 02-02
股市必读：万邦德（002082）预计2025年全年归属净利润亏损9000万元至1.7亿元
万邦德最新公告：石杉碱甲控释片II/III期临床试验完成100例受试者入组
证券之星 · 02-01
万邦德最新公告：石杉碱甲控释片II/III期临床试验完成100例受试者入组
股市必读：万邦德（002082）1月29日收盘跌5.56%，主力净流出3978.37万元
证券之星 · 01-30
股市必读：万邦德（002082）1月29日收盘跌5.56%，主力净流出3978.37万元
万邦德（002082）披露召开2026年第一次临时股东会通知，1月13日股价上涨4.35%
证券之星 · 01-13
万邦德（002082）披露召开2026年第一次临时股东会通知，1月13日股价上涨4.35%
海翔药业最新公告：与万邦德制药签订创新药合作协议双方将围绕渐冻症适应症开展相关合作
证券之星 · 01-12
海翔药业最新公告：与万邦德制药签订创新药合作协议双方将围绕渐冻症适应症开展相关合作
异动快报：万邦德（002082）1月12日10点40分触及涨停板
证券之星 · 01-12
异动快报：万邦德（002082）1月12日10点40分触及涨停板
万邦德(002082.SZ)：阿尔茨海默病项目入选创新药物研发国家科技重大专项
智通财经 · 01-09
万邦德(002082.SZ)：阿尔茨海默病项目入选创新药物研发国家科技重大专项
万邦德（002082）股东赵守明质押760万股，占总股本1.24%
证券之星 · 01-04
万邦德（002082）股东赵守明质押760万股，占总股本1.24%
每周股票复盘：万邦德（002082）子公司WP107获伦理批件
证券之星 · 01-03
每周股票复盘：万邦德（002082）子公司WP107获伦理批件
万邦德(002082.SZ)子公司药品WP107获得伦理批件
智通财经 · 2025-12-29
万邦德(002082.SZ)子公司药品WP107获得伦理批件
异动快报：万邦德（002082）12月25日13点5分触及涨停板
证券之星 · 2025-12-25
异动快报：万邦德（002082）12月25日13点5分触及涨停板
万邦德（002082）披露石杉碱甲控释片Ⅱ、Ⅲ期临床试验完成50例受试者入组，12月15日股价上涨0.41%
证券之星 · 2025-12-15
万邦德（002082）披露石杉碱甲控释片Ⅱ、Ⅲ期临床试验完成50例受试者入组，12月15日股价上涨0.41%
万邦德最新公告：石杉碱甲控释片Ⅱ/Ⅲ期临床试验完成50例受试者入组
证券之星 · 2025-12-12
万邦德最新公告：石杉碱甲控释片Ⅱ/Ⅲ期临床试验完成50例受试者入组
万邦德：石杉碱甲控释片II/III期临床进展顺利
证券之星 · 2025-11-27
万邦德：石杉碱甲控释片II/III期临床进展顺利
万邦德(002082.SZ)：西地那非口服混悬液取得药品注册证书
智通财经 · 2025-11-26
万邦德(002082.SZ)：西地那非口服混悬液取得药品注册证书
加载更多
公司概况
公司名称：
万邦德医药控股集团股份有限公司
所属行业：
医药制造业
上市日期：
2006-11-20
主营业务：
万邦德医药控股集团股份有限公司的主营业务是医药制造和医疗器械的研发、生产、销售。公司的主要产品是心脑血管系统主导产品、神经系统主导产品、呼吸系统主导产品、消化系统主导产品、精神系统主导产品、骨科植入器械、医疗设备及医院工程服务、一次性无菌医用高分子耗材、防护用品。
发行价格：
6.36
{"stockData":{"symbol":"002082","market":"SZ","secType":"STK","nameCN":"万邦德","latestPrice":18.18,"timestamp":1771990200000,"preClose":17.8,"halted":0,"volume":6428796,"delay":0,"changeRate":0.0213,"floatShares":553000000,"shares":612000000,"eps":0.0233,"marketStatus":"午间休市","change":0.38,"latestTime":"02-25 11:30:00","open":17.76,"high":18.45,"low":17.5,"amount":115000000,"amplitude":0.0534,"askPrice":18.18,"askSize":10,"bidPrice":18.15,"bidSize":23,"shortable":0,"etf":0,"ttmEps":0.0233,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1771995600000},"marketStatusCode":3,"adr":0,"adjPreClose":17.8,"symbolType":"stock","openAndCloseTimeList":[[1771983000000,1771990200000],[1771995600000,1772002800000]],"highLimit":19.58,"lowLimit":16.02,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":611689055,"isCdr":false,"pbRate":4.07,"roa":"--","peRate":780.257511,"roe":"0.17%","epsLYR":0.09,"committee":0.602996,"marketValue":11121000000,"turnoverRate":0.0116,"status":0,"floatMarketCap":10058000000},"requestUrl":"/m/hq/s/002082","defaultTab":"news","newsList":[{"id":"2610611751","title":"2月10日万邦德（002082）涨停分析：国家专项、FDA认定、战略合作驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2610611751","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610611751?lang=zh_cn&edition=full","pubTime":"2026-02-10 15:38","pubTimestamp":1770709138,"startTime":"0","endTime":"0","summary":"证券之星消息，万邦德2月10日涨停收盘，收盘价18.59元。今日万邦德涨停的可能因素有：阿尔茨海默病药物石杉碱甲控释片入选国家科技重大专项，正开展国内最大规模Ⅱ/Ⅲ期关键注册临床试验；渐冻症药物获FDA孤儿药认定；与海翔药业等深化战略合作，拓展83亿元ED市场独家进口权；国资股东持股9.8%，强化资源协同；AI医药应用落地加速，推进AI辅助创新药设计及银杏叶滴丸数字化项目。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021000020016.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0004","002082","BK0028","BK0050","BK0239"],"gpt_icon":0},{"id":"2610358696","title":"异动快报：万邦德（002082）2月10日10点10分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2610358696","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610358696?lang=zh_cn&edition=full","pubTime":"2026-02-10 10:10","pubTimestamp":1770689434,"startTime":"0","endTime":"0","summary":"证券之星2月10日盘中消息，10点10分万邦德触及涨停板。其所属行业中药目前上涨。该股为创新药，阿尔茨海默病，化学原料药概念热股，当日创新药概念上涨0.37%，阿尔茨海默病概念上涨0.28%，化学原料药概念上涨0.23%。2月9日的资金流向数据方面，主力资金净流出167.7万元，占总成交额0.66%，游资资金净流入1263.49万元，占总成交额5.0%，散户资金净流出1095.79万元，占总成交额4.34%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021000010246.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0004","BK0050","BK0028","002082","BK0239"],"gpt_icon":0},{"id":"2609614591","title":"万邦德（002082）披露独立董事任期即将届满公告，2月6日股价上涨7.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609614591","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609614591?lang=zh_cn&edition=full","pubTime":"2026-02-06 22:04","pubTimestamp":1770386659,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，万邦德报收于16.72元，较前一交易日上涨7.39%，最新总市值为102.27亿元。近日，万邦德医药控股集团股份有限公司发布《关于独立董事任期即将届满的公告》。公告显示，公司独立董事周岳江先生自2020年2月11日起任职，即将满6年，根据相关规定申请辞去独立董事及董事会下设专门委员会相关职务。其辞职将在公司股东大会选举产生新任独立董事后生效，在此之前仍履行相关职责。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600040535.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0004","002082","BK0050"],"gpt_icon":0},{"id":"2609073593","title":"万邦德：公司医疗设备代理以南非为基地服务南部非洲地区","url":"https://stock-news.laohu8.com/highlight/detail?id=2609073593","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609073593?lang=zh_cn&edition=full","pubTime":"2026-02-06 20:48","pubTimestamp":1770382091,"startTime":"0","endTime":"0","summary":"证券之星消息，万邦德(002082)02月05日在投资者关系平台上答复投资者关心的问题。投资者提问：了解到贵公司的子公司特迈克公司，代理德国、日本、美国等国际医疗设备巨头 40 余个品牌医疗仪器设备的销售和维保业务，请问产品销售到欧盟国家的收入占比为多少？万邦德回复：你好，公司医疗设备代理以南非为基地服务南部非洲地区。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600038478.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159873","002082","BK0050","BK0028","BK0004"],"gpt_icon":0},{"id":"2608857562","title":"万邦德（002082）披露石杉碱甲控释片Ⅱ、Ⅲ期临床试验完成100例受试者入组公告，2月2日股价下跌0.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608857562","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608857562?lang=zh_cn&edition=full","pubTime":"2026-02-02 17:56","pubTimestamp":1770026213,"startTime":"0","endTime":"0","summary":"截至2026年2月2日收盘，万邦德报收于15.6元，较前一交易日下跌0.19%，最新总市值为95.42亿元。万邦德医药控股集团股份有限公司于近日披露《关于石杉碱甲控释片Ⅱ、Ⅲ期临床试验完成100例受试者入组的公告》。公告显示，公司全资子公司万邦德制药集团有限公司的2.2类新药石杉碱甲控释片用于治疗轻、中度阿尔茨海默病型痴呆的II/III期关键注册临床试验已完成100例受试者入组。目前受试者入组短期不会对公司业绩产生重大影响，后续进展存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200026857.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002082","BK0004","BK0028","BK0239","BK0050"],"gpt_icon":0},{"id":"2608896208","title":"股市必读：万邦德（002082）预计2025年全年归属净利润亏损9000万元至1.7亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608896208","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608896208?lang=zh_cn&edition=full","pubTime":"2026-02-02 03:24","pubTimestamp":1769973850,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，万邦德报收于15.63元，上涨1.17%，换手率2.0%，成交量11.06万手，成交额1.72亿元。业绩披露要点业绩预告万邦德发布业绩预告，预计2025年全年归属净利润亏损9000万元至1.7亿元。公司公告汇总2025年度业绩预告万邦德医药控股集团股份有限公司预计2025年度归属于上市公司股东的净利润为-17,000万元至-9,000万元，扣除非经常性损益后的净利润为-18,000万元至-10,000万元。本次业绩预告未经审计，最终数据以2025年年度报告为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200001594.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002082"],"gpt_icon":0},{"id":"2608882004","title":"万邦德最新公告：石杉碱甲控释片II/III期临床试验完成100例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2608882004","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608882004?lang=zh_cn&edition=full","pubTime":"2026-02-01 16:20","pubTimestamp":1769934047,"startTime":"0","endTime":"0","summary":"万邦德(002082.SZ)公告称，公司全资子公司万邦德制药集团有限公司的2.2类新药石杉碱甲控释片用于治疗轻、中度阿尔茨海默病型痴呆的II/III期关键注册临床试验，已完成100例受试者入组。该药物采用双相控释技术，旨在实现快速起效、减少不良反应，并提高患者的用药便利性和长期依从性。试验结果将为产品上市申请提供关键数据支撑。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100003986.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0050","002082","BK0004","BK0239"],"gpt_icon":0},{"id":"2607032195","title":"股市必读：万邦德（002082）1月29日收盘跌5.56%，主力净流出3978.37万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607032195","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607032195?lang=zh_cn&edition=full","pubTime":"2026-01-30 01:04","pubTimestamp":1769706253,"startTime":"0","endTime":"0","summary":"截至2026年1月29日收盘，万邦德报收于15.45元，下跌5.56%，换手率2.36%，成交量13.04万手，成交额2.06亿元。来自公司公告汇总：万邦德2026年第一次临时股东会审议通过《关于子公司签订创新药合作协议的议案》，获99.9925%同意票，中小投资者支持率达99.3933%。交易信息汇总股价提醒1月29日万邦德收盘报15.45元，跌5.56%，当日成交1304.48万元。本次股东会由公司董事会召集，于2026年1月28日以现场和网络投票方式召开。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000000657.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0050","BK0004","BK0239","002082","BK0028"],"gpt_icon":0},{"id":"2603502246","title":"万邦德（002082）披露召开2026年第一次临时股东会通知，1月13日股价上涨4.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603502246","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603502246?lang=zh_cn&edition=full","pubTime":"2026-01-13 17:43","pubTimestamp":1768297394,"startTime":"0","endTime":"0","summary":"截至2026年1月13日收盘，万邦德报收于17.28元，较前一交易日上涨4.35%，最新总市值为105.7亿元。该股当日开盘16.78元，最高17.6元，最低16.05元，成交额达6.2亿元，换手率为6.66%。同日，万邦德发布公告称，公司将于2026年1月28日召开2026年第一次临时股东会，会议由董事会召集，采用现场表决与网络投票相结合的方式进行。股权登记日为2026年1月21日，审议事项包括关于子公司签订创新药合作协议的议案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300030081.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0050","BK0028","002082","BK0004","BK0239"],"gpt_icon":0},{"id":"2602519380","title":"海翔药业最新公告：与万邦德制药签订创新药合作协议双方将围绕渐冻症适应症开展相关合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2602519380","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602519380?lang=zh_cn&edition=full","pubTime":"2026-01-12 19:01","pubTimestamp":1768215702,"startTime":"0","endTime":"0","summary":"海翔药业(002099.SZ)公告称，公司与万邦德制药签订《创新药合作协议》，双方将围绕渐冻症适应症开展相关合作，包括WP205产品的研发和商业化。海翔药业将提供1.5亿元资金，并享有产品商业化后15%的收益权益。该协议需经万邦德医药控股集团股份有限公司股东会审议通过后生效。存在法规政策、市场环境等风险，以及药品研发的高风险特点。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200029909.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","159992","06978","002082","BK0050","BK0188","002099","BK0239","01477","BK0077","BK1574","BK0004","BK1191","BK0028","BK0192"],"gpt_icon":0},{"id":"2602629835","title":"异动快报：万邦德（002082）1月12日10点40分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2602629835","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602629835?lang=zh_cn&edition=full","pubTime":"2026-01-12 10:45","pubTimestamp":1768185923,"startTime":"0","endTime":"0","summary":"证券之星1月12日盘中消息，10点40分万邦德触及涨停板。其所属行业中药目前下跌。领涨股为万邦德。该股为医疗器械，骨科材料，新冠病毒防治概念热股，当日医疗器械概念上涨1.16%，骨科材料概念上涨1.07%，新冠病毒防治概念上涨1.04%。1月9日的资金流向数据方面，主力资金净流入3280.92万元，占总成交额11.32%，游资资金净流出728.13万元，占总成交额2.51%，散户资金净流出2552.79万元，占总成交额8.81%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200007919.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0004","BK0050","BK0028","002082","BK0239"],"gpt_icon":0},{"id":"2602328935","title":"万邦德(002082.SZ)：阿尔茨海默病项目入选创新药物研发国家科技重大专项","url":"https://stock-news.laohu8.com/highlight/detail?id=2602328935","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602328935?lang=zh_cn&edition=full","pubTime":"2026-01-09 15:50","pubTimestamp":1767945036,"startTime":"0","endTime":"0","summary":"智通财经APP讯，万邦德(002082.SZ)公告，公司全资子公司万邦德制药集团有限公司(“万邦德制药”)阿尔茨海默病项目入选了由中国科学院上海药物研究所牵头的创新药物研发国家科技重大专项项目，已收到国家卫生健康委员会中国生物技术发展中心下发的立项批复。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390867.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0050","BK1161","159992","BK0239","BK1574","BK0004","002082","06978"],"gpt_icon":0},{"id":"2600006042","title":"万邦德（002082）股东赵守明质押760万股，占总股本1.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2600006042","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600006042?lang=zh_cn&edition=full","pubTime":"2026-01-04 18:18","pubTimestamp":1767521904,"startTime":"0","endTime":"0","summary":"证券之星消息，万邦德1月4日公开信息显示，股东赵守明向浙江浙里金融信息服务有限公司合计质押760.0万股，占总股本1.24%。质押详情见下表：截止本公告日，股东万邦德集团有限公司已累计质押股份1.53亿股，占其持股总数的86.83%，股东赵守明已累计质押股份3588.96万股，占其持股总数的96.3%，股东庄惠已累计质押股份985.0万股，占其持股总数的34.89%。万邦德主营业务：医药制造、医疗器械大健康产业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010400003407.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0004","BK0239","002082","BK0050"],"gpt_icon":0},{"id":"2600806092","title":"每周股票复盘：万邦德（002082）子公司WP107获伦理批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2600806092","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600806092?lang=zh_cn&edition=full","pubTime":"2026-01-03 03:46","pubTimestamp":1767383172,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，万邦德报收于13.93元，较上周的13.7元上涨1.68%。本周，万邦德12月31日盘中最高价报14.16元。本周关注点公司公告汇总：子公司药品WP107获伦理批件，将开展I期临床试验公司公告汇总万邦德医药控股集团股份有限公司全资子公司万邦德制药集团有限公司的新药WP107口服溶液治疗重症肌无力的I期临床试验，已获得温州医科大学附属第二医院医学伦理委员会审查批件，同意开展临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010300002345.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0050","BK0004","BK0028","002082"],"gpt_icon":0},{"id":"2595856987","title":"万邦德(002082.SZ)子公司药品WP107获得伦理批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2595856987","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595856987?lang=zh_cn&edition=full","pubTime":"2025-12-29 17:09","pubTimestamp":1766999391,"startTime":"0","endTime":"0","summary":"智通财经APP讯，万邦德(002082.SZ)发布公告，公司全资子公司万邦德制药集团有限公司的新药WP107治疗重症肌无力的I期临床试验获得了温州医科大学附属第二医院温州医科大学附属育英儿童医院医学伦理委员会的审查批件，批准项目开展。公司获得国家药监局的《药物临床试验批准通知书》后，积极推进药学和临床工作，已正式开展I期临床试验工作。此次收到温州医科大学附属第二医院温州医科大学附属育英儿童医院医学伦理委员会的审查批件，旨在比较石杉碱甲口服溶液和石杉碱甲注射液在中国健康受试者空腹状态下单次给药的药代动力学特征，评估石杉碱甲口服溶液的相对生物利用度及空腹状态下两种制剂的安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386546.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","002082","BK0050","BK0028","BK0004"],"gpt_icon":0},{"id":"2594282334","title":"异动快报：万邦德（002082）12月25日13点5分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2594282334","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594282334?lang=zh_cn&edition=full","pubTime":"2025-12-25 13:10","pubTimestamp":1766639443,"startTime":"0","endTime":"0","summary":"证券之星12月25日盘中消息，13点5分万邦德触及涨停板。其所属行业中药目前上涨。该股为骨科材料，医疗器械，新冠病毒防治概念热股，当日骨科材料概念上涨0.8%，医疗器械概念上涨0.68%，新冠病毒防治概念上涨0.23%。12月24日的资金流向数据方面，主力资金净流入2808.31万元，占总成交额9.2%，游资资金净流入2191.93万元，占总成交额7.18%，散户资金净流出5000.24万元，占总成交额16.38%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122500016378.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002082","BK0050","BK0028","BK0004"],"gpt_icon":0},{"id":"2591961795","title":"万邦德（002082）披露石杉碱甲控释片Ⅱ、Ⅲ期临床试验完成50例受试者入组，12月15日股价上涨0.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591961795","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591961795?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:58","pubTimestamp":1765792712,"startTime":"0","endTime":"0","summary":"截至2025年12月15日收盘，万邦德报收于12.27元，较前一交易日上涨0.41%，最新总市值为75.05亿元。该股当日开盘12.15元，最高12.79元，最低12.09元，成交额达1.5亿元，换手率为2.19%。公司近日发布公告称，其全资子公司万邦德制药集团有限公司的2.2类新药石杉碱甲控释片用于治疗轻、中度阿尔茨海默病型痴呆的II/III期关键注册临床试验，近日完成50例受试者入组。石杉碱甲控释片采用双相控释技术，支持每日一次给药，旨在提升用药依从性和安全性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500023516.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002082","BK0239","BK0050","BK0004","BK0028"],"gpt_icon":0},{"id":"2590509000","title":"万邦德最新公告：石杉碱甲控释片Ⅱ/Ⅲ期临床试验完成50例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2590509000","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590509000?lang=zh_cn&edition=full","pubTime":"2025-12-12 21:10","pubTimestamp":1765545021,"startTime":"0","endTime":"0","summary":"万邦德(002082.SZ)公告称，公司全资子公司万邦德制药集团有限公司的2.2类新药石杉碱甲控释片用于治疗轻、中度阿尔茨海默病型痴呆的II/III期关键注册临床试验，已完成50例受试者入组。该临床研究是中国目前已知规模最大的阿尔茨海默病注册研究，旨在验证药物的安全性、有效性，为产品最终上市申请提供关键数据支撑。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200038760.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0004","BK0050","BK0028","BK0239","002082"],"gpt_icon":0},{"id":"2586240100","title":"万邦德：石杉碱甲控释片II/III期临床进展顺利","url":"https://stock-news.laohu8.com/highlight/detail?id=2586240100","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586240100?lang=zh_cn&edition=full","pubTime":"2025-11-27 20:48","pubTimestamp":1764247706,"startTime":"0","endTime":"0","summary":"目前公司石杉碱甲控释片II/III期关键注册临床进展顺利，该临床研究是中国目前已知规模最大的阿尔茨海默病注册研究，公司积极与CRO公司紧密协作力争尽快取得更多有效数据验证药品的疗效和安全性。已有数据显示，石杉碱甲控释片安全性好，石杉碱甲在适当剂量下可显著改善患者的认知功能。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112700035365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0004","BK0239","002082","BK0050"],"gpt_icon":0},{"id":"2586232162","title":"万邦德(002082.SZ)：西地那非口服混悬液取得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2586232162","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586232162?lang=zh_cn&edition=full","pubTime":"2025-11-26 16:52","pubTimestamp":1764147159,"startTime":"0","endTime":"0","summary":"智通财经APP讯，万邦德 发布公告，公司全资子公司万邦德制药集团浙江医药销售有限公司获得西班牙Farmalider,S.A.的枸橼酸西地那非口服混悬液在中国大陆市场10年的独家进口权和独家销售权，近日收到Farmalider授权方NULIFE GROUPE LIMITED礼易集团有限公司的通知，获悉西地那非口服混悬液已取得国家药品监督管理局核准签发的《药品注册证书》。西地那非口服混悬液取得《药品注册证书》，标志着公司未来10年可独家进行该产品在中国大陆市场的进口和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1373878.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"万邦德(002082.SZ)：西地那非口服混悬液取得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0239","BK0004","002082","BK0050"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1771990251370,"stockEarnings":[{"period":"1week","weight":-0.0028},{"period":"1month","weight":0.0539},{"period":"3month","weight":0.3619},{"period":"6month","weight":0.8956},{"period":"1year","weight":2.0118},{"period":"ytd","weight":0.2778}],"compareEarnings":[{"period":"1week","weight":0.0087},{"period":"1month","weight":-0.0045},{"period":"3month","weight":0.0655},{"period":"6month","weight":0.0712},{"period":"1year","weight":0.2207},{"period":"ytd","weight":0.0374}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"万邦德医药控股集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"26415人(较上一季度减少83.49%)","perCapita":"20944股","listingDate":"2006-11-20","address":"浙江省湖州市吴兴区织里镇栋梁路1688号","registeredCapital":"61168万元","survey":" 万邦德医药控股集团股份有限公司的主营业务是医药制造和医疗器械的研发、生产、销售。公司的主要产品是心脑血管系统主导产品、神经系统主导产品、呼吸系统主导产品、消化系统主导产品、精神系统主导产品、骨科植入器械、医疗设备及医院工程服务、一次性无菌医用高分子耗材、防护用品。","listedPrice":6.36},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"万邦德(002082)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供万邦德(002082)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"万邦德,002082,万邦德股票,万邦德股票老虎,万邦德股票老虎国际,万邦德行情,万邦德股票行情,万邦德股价,万邦德股市,万邦德股票价格,万邦德股票交易,万邦德股票购买,万邦德股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"万邦德(002082)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供万邦德(002082)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}